On behalf of Taiho Oncology, Inc., we are pleased to inform you that a corporate press release, “ASTEX PHARMACEUTICALS, TAIHO ONCOLOGY, AND OTSUKA PHARMACEUTICAL ANNOUNCE FDA AND HEALTH CANADA APPROVAL OF INQOVI® (DECITABINE AND CEDAZURIDINE) TABLETS, ORAL HYPOMETHYLATING AGENT (HMA) THERAPY FOR INTERMEDIATE AND HIGH-RISK MDS AND CMML" has been issued July 7, 2020.
https://www.taihooncology.com/us/news/2020-07-inqovi-approval/